
Guggenheim analyst Debjit Chattopadhyay lowered the firm’s price target on Entrada Therapeutics (TRDA) to $13 from $17 and keeps a Buy rating on the shares. Interim Phase 1/2 data on
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TRDA | Entrada Therapeutics Inc | 4.35 | -5.76 | -56.97% |
| Name | Price | % Change | |
|---|---|---|---|
| $4.35 | -56.97% |

Guggenheim analyst Debjit Chattopadhyay lowered the firm’s price target on Entrada Therapeutics (TRDA) to $13 from $17 and keeps a Buy rating on the shares. Interim Phase 1/2 data on

Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $10 from $11 and keeps a Buy rating on the shares. The firm states that October’s ENTR-601-45 biomarker

Reports Q3 revenue $905,000, consensus $5.87M. “The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs,” said Dipal Doshi,

Entrada Therapeutics (TRDA) announced the appointment of Linea Aspesi as chief people officer. Prior to Entrada, Aspesi served as chief people officer at KalVista Pharmaceuticals. Published first on TheFly –

An announcement from Entrada Therapeutics Inc ( ($TRDA) ) is now available. On October 14, 2026, Entrada Therapeutics reported positive topline results from Cohort 1 of its global Phase 1/2

Entrada Therapeutics (TRDA) announced topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose, or MAD, portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 in ambulatory

Roth Capital raised the firm’s price target on Entrada Therapeutics (TRDA) to $11 from $10 and keeps a Buy rating on the shares after the company reported Q2 earnings and

Reports Q2 revenue $898,000, consensus $2.23M. “With multiple data readouts ahead in 2026, we are well positioned to deliver on important clinical milestones and further demonstrate the potential of our

Entrada Therapeutics Inc ( ($TRDA) ) has issued an announcement. Entrada Therapeutics Inc. held its Annual Meeting of stockholders on June 10, 2026, with 33,190,234 of 38,820,616 eligible common shares

Guggenheim lowered the firm’s price target on Entrada Therapeutics (TRDA) to $17 from $20 and keeps a Buy rating on the shares. A clean safety profile will be needed to
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 17, 2027TBA | $170.30M | $-0.99 | $2.80M | 0.01 | -1.13 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.